Aspen Pharmacare has announced that it will not be manufacturing the lenacapavir HIV prevention injection, and that it will instead focus on producing alimatravir, an experimental HIV prevention pill. Catherine Tomlinson explores the reasoning behind Aspen’s decision and assesses what it all means for local pharmaceutical production.
From the first reported cases of HIV in 1981 to the latest breakthroughs in long-acting prevention, this Spotlight timeline traces key moments in the global and South African response to the virus. It highlights scientific milestones, political controversies, activism, and the human stories that shaped one of the most significant public health challenges of our time.
Spotlight has launched a new HIV dashboard and graph generator based on outputs from the Thembisa model. Our hope is that this dashboard will help the public and people working in healthcare to find important HIV numbers more easily. Please take a look and let us know what you think of it.
The health department has plans to roll out lenacapavir, a twice-yearly HIV prevention injection, in a select group of public sector clinics by April 2026. Meanwhile, little progress has been made towards rolling out a two-monthly prevention injection, despite the four-year head start this product had on lenacapavir. Catherine Tomlinson reports.
